ArticleFrontiers in oncology2025
Solitary testicular metastasis post-prostatectomy for prostatic ductal adenocarcinoma: case report and literature review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Solitary Testicular Metastasis From Ductal Prostate Cancer 5 Years After Radical Prostatectomy: A Case Report.Case reports in urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Purpose: Prostatic ductal adenocarcinoma (PDA) constitutes a rare and notably aggressive histological subtype within the spectrum of prostate malignancies, distinguished by a heightened propensity for recurrence and metastasis compared to prostatic acinar adenocarcinoma (PAA). Testicular metastasis in PDA is exceptionally rare. Despite sporadic reports in the literature, a consensus regarding the optimal therapeutic approach remains elusive. This study retrospectively analyzes a singular case of PDA manifesting with solitary testicular metastasis after laparoscopic radical prostatectomy (LRP), consolidating insights into clinical, histopathological, molecular, and therapeutic aspects, alongside existing scholarly discourse. Methods: We present the case of a 63-year-old gentleman diagnosed with pure PDA (pT3aN0, Gleason score 4 + 4 = 8), exhibiting a serum prostate-specific antigen (PSA) level exceeding 100 ng/ml. Subsequently, the patient underwent androgen deprivation therapy (ADT) followed by LRP. Subsequently, at 17 months post-LRP, local recurrence and a right testicular mass emerged, prompting pelvic radiotherapy and docetaxel chemotherapy. Ultimately, the patient underwent right orchiectomy 65 months post-LRP, with pathological findings confirming metastatic PDA. Four months post-orchiectomy, PSA levels declined to 1.77 ng/ml. Additionally, a comprehensive review of published literature concerning PDA complicated by testicular metastasis was conducted. Results: The patient derived therapeutic benefits from ADT, LRP, radiation therapy, and orchiectomy, resulting in objective symptom alleviation and a reduction in PSA. Nevertheless, docetaxel proved inefficacious. The literature review indicated variability in outcomes across diverse treatment modalities. Conclusions: Prolonged surveillance is imperative for patients diagnosed with PDA. Urologists must remain vigilant regarding uncommon sites of metastasis, particularly in instances of elevated PSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.